Journal
PEERJ
Volume 10, Issue -, Pages -Publisher
PEERJ INC
DOI: 10.7717/peerj.13141
Keywords
Desmoglein 2; Cancer; Prognosis; Systematic review; Meta-analysis
Categories
Funding
- Scientific Research Foundation of the Health Planning Committee of Sichuan [18PJ186]
- National Natural Science Foundation of China [81600864]
- Undergraduate Student Innovation and Entrepreneurship Training Program of Sichuan University [C202114146]
- Swedish Cancer Society [19-0056-JiA]
Ask authors/readers for more resources
This systematic review and meta-analysis found that high expression of Desmoglein 2 (DSG2) is associated with worse prognosis in patients with non-small cell lung cancer (NSCLC), suggesting that DSG2 expression could serve as a biomarker for prognosis in NSCLC.
Objective: The survival and clinicopathological significance of desmoglein 2 (DSG2) in various cancers is controversial. Thus, we performed this systematic review and meta-analysis to explore the preliminary prognostic value of DSG2. Methods: Eligible studies were identified from databases including PubMed, the Cochrane Library, Embase, Web of Science and Scopus. Hand searches were also conducted in relevant bibliographies. We then extracted and pooled hazard ratio (HR) of overall survival (OS) and odds ratio (OR) of clinicopathological features. Results: A total of 11 eligible studies containing 1,488 patients were included. Our results demonstrated that in non-small cell lung cancer (NSCLC), high DSG2 expression is associated with poor OS. However, in digestive system cancer and female reproductive system cancer, there were no statistically significant associations between OS and DSG2. Conclusions: Based on the findings of this study, high DSG2 expression is associated with worse prognosis in patients with NSCLC, and thus DSG2 expression could be a biomarker for prognosis in NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available